Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Fosun Pharma to buy 74...

    Fosun Pharma to buy 74 percent stake in Gland Pharma for 1.1 billion dollar

    Written by Ruby Khatun Khatun Published On 2017-09-19T10:47:47+05:30  |  Updated On 18 Aug 2021 12:17 PM IST

    BEIJING/MUMBAI: Shanghai Fosun Pharmaceutical Group is trimming the size of the stake it will buy in India's Gland Pharma to 74 percent for $1.1 billion, in a bid to salvage the stalled deal that would be the biggest takeover by a Chinese firm in India.


    Fosun Pharma had struck a deal in July last year to buy an 86 percent stake valued at about $1.26 billion in the Indian generic injectable drugmaker, but the deal had raised concerns among some in the Indian government, a source had told Reuters previously.


    India allows foreign investment of up to 100 percent in its pharmaceutical sector but above 74 percent requires government approval.


    Two sources with knowledge of the matter told Reuters that the Chinese drugmaker had agreed to lower the stake it planned to acquire in Gland to 74 percent, mainly because it sought to get the deal completed more smoothly and faster. The Gland is backed by private equity firm KKR & Co LP.


    Fosun said in a statement on Sunday the deal no longer required a nod from India's Cabinet Committee on Economic Affairs, chaired by Prime Minister Narendra Modi. It said it had already received approval from Chinese regulators and applied for antitrust approval in the United States and India.


    The Chinese drugmaker added that Gland Pharma's founding family wanted to retain a bigger holding in the Indian company because of its good performance.


    Gland managing director Ravi Penmetsa told Reuters some approvals the original deal had received were at risk of expiring.


    "Now with this new agreement, we won't have to reapply for those," he said, adding that he expects the deal to be completed in two weeks.


    Fosun Pharma's parent, Fosun International, has been the poster child for China's decade-long overseas push that saw Chinese bidders spend a record $105 billion on assets ranging from film studios to football clubs in 2016.


    Best known outside China for its acquisition of French resort chain Club Med, Fosun International was among acquisitive firms that found itself in the cross-hairs of Chinese authorities, sources have said.


    But its executives said in late August that Fosun would continue to conduct overseas deals and scout for targets in areas including drug manufacturing.


    Fosun Pharma said in mid-August it was bidding for a stake in U.S. specialty drugmaker Arbor Pharmaceuticals LLC.


    On Sunday Fosun Pharma said it would spend no more than $25 million to market the Indian company's enoxaparin blood-thinning drug in the United States, when it obtains approval there, cutting the previously proposed marketing spend by half.


    In a statement on Sunday, Gland said the deal would allow it to make biosimilars - lucrative copies of biotech drugs - at Fosun's site and sell them in India.


    "It won't happen overnight, but we have started working on it," Penmetsa said.


    Penmetsa and his father, P.V.N. Raju, will remain on the Gland board and the current management team will continue to run the company.




    (Reporting by Dominique Patton in BEIJING and Zeba Siddiqui in MUMBAI; Additional reporting by Julie Zhu and Elzio Barreto in HONG KONG; Editing by David Goodman and Muralikumar Anantharaman)



    74 percent stakebuyFosun PharmaFosun Pharmaceutical GroupgenericGland PharmaIndiainjectableKKRNarendra ModiP V N Rajupharmaceutical sectorPrime MinisterRavi Penmetsa
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok